When it comes to cancer, the most important step is often the one you take before you even feel sick. For many people, colorectal cancer screening is a vital part of staying healthy. However, choosing the right test can feel overwhelming. Some people might not know which test is best for them, or they might feel unsure about the risks and benefits of different options. This uncertainty can lead to people putting off their screenings entirely.
To see if personalized information could help, researchers conducted a study involving over 1,000 patients between the ages of 50 and 75. These individuals were at average risk for colorectal cancer and were preparing for upcoming clinic appointments. The researchers split the group into two. One group received a decision aid that included personalized information about their specific risk for advanced colorectal neoplasia (which are precancerous growths). The other group received a decision aid with only general information. Additionally, some doctors received personalized risk notes for their patients, while others received standard notifications.
The results showed that patients who received personalized risk information were much more likely to say they intended to get screened at all. Specifically, they showed a much higher interest in taking a stool test compared to the group that received only general information. Interestingly, the group with personalized information showed a lower interest in undergoing a colonoscopy. While the study did not show a clear, universal change in how well patients and doctors agreed on the final plan across all settings, it did find that in one specific health system, giving doctors personalized notes helped patients feel more in sync with their providers. It is important to keep a few things in mind before making big changes. This study was conducted in only one city and only included English-speaking patients. Because of this, the results might not apply to everyone in every location. Also, the study did not have a large number of patients who were at a high risk for advanced growths, which could affect how the data looks for some people.
For now, this research suggests that giving patients specific, personalized information about their risks can be a powerful tool. It helps them feel more informed when making big decisions about their health. If you are approaching your next screening, you might find it helpful to ask your doctor for specific details about your personal risk level to help you choose the best path forward.
